건강 보도자료
-
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Takeda (TSE:4502/NYSE:TAK ) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and gran...
- 03월 04일 11:11
전시회
